Dutch SME specializing in radiomics — AI-driven medical imaging analysis for personalized lung cancer and metastatic disease treatment.
PT Theragnostic is a Dutch SME specializing in radiomics — the extraction of quantitative imaging features from medical scans to guide personalized cancer treatment. They develop computational tools that analyze tumor heterogeneity from CT and MRI data, enabling non-invasive patient stratification without additional biopsies. Their work focuses heavily on lung cancer and metastatic disease, combining imaging analytics with emerging immunotherapy and radiation therapy approaches. Based in Maastricht, they operate at the intersection of medical imaging, data science, and clinical oncology.
RAIL (radiomics of lung cancer for tumour heterogeneity stratification), REACT (radiomics for MRI-based personalised treatment), and RADIATE (radiation therapy innovations) all center on imaging-based treatment guidance.
RAIL focused specifically on non-invasive stratification of lung tumour heterogeneity; IMMUNOSABR targeted lung cancer and metastatic cancer treatment.
IMMUNOSABR explored clinical proof of concept for combining immunotherapy (L19-IL2) with stereotactic ablative body radiotherapy (SABR).
REACT specifically addressed optimising radiomics techniques for MRI-guided personalized cancer treatment.
PT Theragnostic's early H2020 work (2015) focused on foundational radiomics and radiation therapy education through RAIL and RADIATE, establishing their core competency in imaging-based tumor analysis. By 2017, their focus shifted toward clinical application, combining radiomics with immunotherapy (IMMUNOSABR) and extending their imaging analytics from CT to MRI (REACT). This trajectory shows a clear move from building radiomics tools toward translating them into specific clinical treatment protocols, particularly for lung and metastatic cancers.
PT Theragnostic is moving from pure imaging analytics toward clinical integration of radiomics with immunotherapy, positioning them for the growing precision oncology market.
PT Theragnostic operates as a project leader — they coordinated 2 of their 4 projects, including RAIL (their largest at EUR 2.4M). With 30 unique consortium partners across 8 countries from just 4 projects, they build broad networks rather than relying on repeat collaborators. Their mix of coordination, partnership, and third-party roles suggests flexibility — they can lead research agendas or contribute specialized radiomics expertise to larger clinical consortia.
They have collaborated with 30 unique partners across 8 countries from only 4 projects, indicating they build large, diverse consortia. Their Maastricht base places them in the MAASTRO/Maastricht University oncology research ecosystem, a strong European hub for radiation oncology.
PT Theragnostic occupies a rare niche as an SME that bridges medical imaging data science and clinical oncology — most radiomics work sits inside university hospitals, but they operate as an independent commercial entity. Their ability to coordinate multi-million euro EU projects (RAIL, EUR 2.4M) as a small company demonstrates strong scientific credibility and project management capacity. For consortium builders, they offer specialized radiomics and imaging analytics expertise without the overhead and IP complexity of partnering with a large hospital.
